Urisept - Synthetic antimicrobial drug with broad spectrum bactericidal action. Urisept has a bacteriostatic action, which is associated with inhibition of recycling process of PABA and a violation dihydrofolic acid\'s synthesis in bacterial cells. Trimethoprim inhibits the enzyme that is involved in the metabolism of folic acid converting dihydrofolate to tetrahydrofolate. Thus it is blocked two successive stages of the biosynthesis of purines and therefore nucleic acids that are essential for growth and reproduction of bacteria. High concentrations created in the tissues of the lung, kidney, prostate, cerebrospinal fluid, bile, bones.
Co-trimoxazole is active against gram-positive bacteria: Staphylococcus spp. (including strains of penicillinase producing), Streptococcus spp. (including Streptococcus pneumoniae), Corynebacterium diphtheriae; gram-negative bacteria: Neisseria gonorrhoeae, Escherichia coli, Shigella spp., Salmonella spp., Proteus spp., Enterobacter spp., Klebsiella spp., Yersinia spp., Vibrio cholerae, Haemophilus influenzae; anaerobic asporogenous bacteria - Bacteroides spp. Co-trimoxazole is active also against Chlamydia spp.
Pseudomonas aeruginosa, Treponema spp., Mycoplasma spp., Mycobacterium tuberculosis and also viruses and fungi are resistant to co-trimoxazole.
Indications: bacterial infections, pneumocystis pneumonia
Treatment of enteritis; treatment of Pneumocystis carinii pneumonia; treatment of severe or complicated UTIs caused by susceptible strains of bacteria.-Treatment of acute otitis media and acute exacerbations of chronic bronchitis; treatment of traveler’s diarrhea; treatment and prophylaxis of P. carinii pneumonia; Shigella enteritis; UTIs caused by susceptible strains of bacteria.-Treatment of cholera, salmonella-type infections, and nocardiosis; prevention of recurrent UTIs in women; prophylaxis of bacterial infections in susceptible patients; treatment of acute and chronic bacterial prostatitis; treatment of skin and soft-tissue infections caused by Staphylococcus aureus.